Our team at Boston Biotech Advisors can significantly boost your odds of a successful IDE submission.

At our consulting firm, we specialize in assisting pharmaceutical companies navigate the complex process of demonstrating bioequivalence.

AI is optimizing the path medications take from lab to patient, making drug development not only faster but more economical and precise.

The landscape of mental health treatment is undergoing a remarkable transformation with medicinal psychedelics like psilocybin and MDMA.

Exploring common issues with submissions to the FDA and EMA and how to avoid them.